Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Michael Stierman

Nurse Practitioner, Family Perrysburg, OH Nurse Practitioner

NPI 1194977900 CMS profile 11137892

12780 Roachton Rd 1, Perrysburg, OH 43551

Open in the dashboard

General payments

$44,507

611 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Michael Stierman of Perrysburg, OH is reported in the CMS Open Payments database as having received $44,507 across 611 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $9,945 115
2024 General $11,258 141
2023 General $19,159 139
2022 General $2,338 104
2021 General $1,807 112

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michael Stierman
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Michael Stierman were reported at $9,945. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Michael Stierman Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $1,807 $124 $35–$379 $132
2022 $2,338 $141 $44–$430 $149
2023 $19,159 $154 $49–$476 $160
2024 $11,258 $165 $51–$504 $164
2025 $9,945 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. UCB, Inc. $31,758 96 payments
  2. E.R. Squibb & Sons, L.L.C. $2,993 44 payments
  3. Novartis Pharmaceuticals Corporation $1,894 71 payments
  4. Janssen Biotech, Inc. $1,600 64 payments
  5. AbbVie, Inc. $1,571 107 payments
  6. Regeneron Healthcare Solutions, Inc. $679 23 payments
  7. Genzyme Corporation $582 32 payments
  8. Sun Pharmaceutical Industries Inc. $566 29 payments
  9. Pfizer Inc. $458 29 payments
  10. Incyte Corporation $418 16 payments
  11. Other $1,988 100 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $28,078 20 payments
  2. Food and Beverage $10,936 566 payments
  3. Travel and Lodging $3,468 14 payments
  4. Consulting Fee $1,578 4 payments
  5. Education $447 7 payments
Products named General payments · program years 2021–2025
  1. Bimzelx $18,820 48 payments
  2. Cimzia $5,897 41 payments
  3. SOTYKTU $2,043 40 payments
  4. TREMFYA $1,539 45 payments
  5. COSENTYX Dermatology $867 43 payments
  6. DUPIXENT Immunology $811 44 payments
  7. SKYRIZI $780 51 payments
  8. COSENTYX Immunology $600 23 payments
  9. DUPIXENT Inflammation And Immunology $495 16 payments
  10. ILUMYA $457 25 payments
  11. Other $4,732 301 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 20 drugs

Part D claims

677

Median for Nurse Practitioner: 389

Drug cost

$245,975

Median for Nurse Practitioner: $21,885

Branded share of claims

5.5%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Cosentyx Unoready Pen Secukinumab Brand 11 $169,063
Otezla Apremilast Brand 12 $58,946
Clobetasol Propionate Generic 102 $6,155
Fluorouracil Generic 34 $2,354
Ketoconazole Generic 138 $1,964
Triamcinolone Acetonide Generic 119 $1,347
Doxycycline Hyclate Generic 32 $977
Fluocinonide Generic 27 $870
Minocycline Hcl Generic 25 $836
Clindamycin Phosphate Generic 14 $819

The 10 drugs with the highest cost, of 20 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 34 billing codes

Paid by Medicare

$109,925

Of which drugs: $42,884

Medicare patients

515

Average age 74

Services billed

2,418

116 women, 399 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 72%
Arthritis 44%
Ischemic heart disease 24%
Diabetes 23%
Chronic kidney disease 18%
Cancer 17%
Atrial fibrillation 16%
Depression 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 24 152 $107

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 20 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Bimzelx
  • UCB, Inc. $9,170
$9,170 — —
TREMFYA
  • Janssen Biotech, Inc. $403
$403 — —
SOTYKTU
  • E.R. Squibb & Sons, L.L.C. $215
$215 — —
DUPIXENT
  • GENZYME CORPORATION $123
  • Regeneron Healthcare Solutions, Inc. $85
$208 — —
SKYRIZI
  • AbbVie, Inc. $187
$187 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 20 in the dashboard with a free account

Records

611 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record